Symbols / CUE $0.31 +0.65%
CUE Chart
About
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 28.47M |
| Enterprise Value | 10.16M | Income | -37.68M | Sales | 7.10M |
| Book/sh | 0.17 | Cash/sh | 0.26 | Dividend Yield | — |
| Payout | 0.00% | Employees | 41 | IPO | — |
| P/E | — | Forward P/E | -0.65 | PEG | — |
| P/S | 4.01 | P/B | 1.84 | P/C | — |
| EV/EBITDA | -0.27 | EV/Sales | 1.43 | Quick Ratio | 1.46 |
| Current Ratio | 1.66 | Debt/Eq | 46.60 | LT Debt/Eq | — |
| EPS (ttm) | -0.41 | EPS next Y | -0.48 | EPS Growth | — |
| Revenue Growth | -35.60% | Earnings | 2025-11-12 16:00 | ROA | -62.30% |
| ROE | -195.19% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -3.51% | Profit Margin | 0.00% | Shs Outstand | 91.24M |
| Shs Float | 78.26M | Short Float | 2.17% | Short Ratio | 1.59 |
| Short Interest | — | 52W High | 1.12 | 52W Low | 0.23 |
| Beta | 1.55 | Avg Volume | 1.27M | Volume | 1.58M |
| Target Price | $4.00 | Recom | None | Prev Close | $0.31 |
| Price | $0.31 | Change | 0.65% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.00
Mean price target
2. Current target
$0.31
Latest analyst target
3. DCF / Fair value
$-2.90
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.31
Low
$4.00
High
$4.00
Mean
$4.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-25 | init | LUCID CAPITAL MARKETS | — → Buy | $4 |
| 2025-04-02 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $2 |
| 2024-08-20 | main | Stifel | Buy → Buy | $4 |
| 2024-07-26 | main | JMP Securities | Market Outperform → Market Outperform | $2 |
| 2024-07-26 | main | Piper Sandler | Overweight → Overweight | $3 |
| 2024-04-09 | main | Stifel | Buy → Buy | $8 |
| 2024-04-09 | main | Oppenheimer | Outperform → Outperform | $10 |
| 2024-04-03 | reit | Piper Sandler | Overweight → Overweight | $8 |
| 2024-03-13 | init | Jefferies | — → Buy | $6 |
| 2023-11-06 | main | Piper Sandler | Overweight → Overweight | $8 |
| 2023-06-15 | reit | Stifel | Buy → Buy | $8 |
| 2023-05-15 | reit | JMP Securities | Outperform → Outperform | $15 |
| 2023-03-22 | main | Stifel | — → Buy | $8 |
| 2023-03-22 | reit | Oppenheimer | — → Outperform | $10 |
| 2022-11-21 | init | Piper Sandler | — → Overweight | $7 |
| 2022-08-24 | main | Oppenheimer | — → Outperform | $10 |
| 2022-03-21 | main | Oppenheimer | — → Outperform | $26 |
| 2022-03-18 | main | Craig-Hallum | — → Buy | $26 |
| 2020-11-24 | init | Berenberg | — → Buy | $30 |
| 2020-05-20 | main | Stifel | — → Buy | $30 |
News
RSS: Latest CUE news- How Prior Military Actions Cue The Current Stock Market - Investor's Business Daily ue, 03 Mar 2026 14
- Cue Energy Resources Surges on Surprise Takeover Play - TipRanks Sat, 07 Mar 2026 20
- Cue Biopharma Names Lucinda Warren Chief Financial Officer - The Globe and Mail Fri, 13 Feb 2026 08
- Cue Biopharma Announces Proposed Public Offering - GlobeNewswire hu, 18 Dec 2025 08
- Cue Biopharma (CUE) Price Target Increased by 25.00% to 5.10 - Nasdaq Fri, 05 Dec 2025 08
- Autoimmune drug candidate CUE-401 passes early safety tests in animals - Stock Titan ue, 17 Feb 2026 08
- Cue Biopharma Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis Sat, 20 Dec 2025 08
- Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance Wed, 12 Nov 2025 08
- Cue Biopharma stock tumbles on public offering announcement - Investing.com hu, 18 Dec 2025 08
- ‘We’re not in a bubble yet’ because only 3 out of 4 conditions are met, top economist says. Cue the OpenAI IPO - Fortune Sun, 01 Feb 2026 08
- 12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga Fri, 06 Mar 2026 12
- Cue Biopharma (NASDAQ: CUE) signs ImmunoScape cell therapy pact; $15M upfront, 40% stake - Stock Titan hu, 06 Nov 2025 08
- $CUE stock is up 20% today. Here's what we see in our data. - Quiver Quantitative Mon, 05 Jan 2026 08
- Cue Biopharma stock rating reiterated at Market Outperform by Citizens - Investing.com ue, 18 Nov 2025 08
- Biotech Stocks Surge After Hours: IO Biotech Jumps 19%, Cue Biopharma And Cabaletta Bio Follow - Nasdaq Wed, 21 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 323857 | 99747 | — | Purchase at price 0.30 - 0.32 per share. | SARRAF PASHA | Director | — | 2025-12-30 00:00:00 | D |
| 1 | 30000 | 30900 | — | Purchase at price 1.03 per share. | PASSERI DANIEL R | Chief Executive Officer | — | 2024-12-16 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.27 |
| NormalizedEBITDA | -37.62M | -45.90M | -50.77M | -43.67M |
| TotalUnusualItems | 93.00K | -157.00K | 277.00K | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 93.00K | -157.00K | 277.00K | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -40.67M | -50.73M | -53.01M | -44.16M |
| ReconciledDepreciation | 2.35M | 3.44M | 1.81M | -1.78M |
| EBITDA | -37.53M | -46.05M | -50.49M | -43.67M |
| EBIT | -39.88M | -49.49M | -52.30M | -43.67M |
| NetInterestIncome | 826.00K | 1.42M | 215.00K | 45.90K |
| InterestExpense | 796.00K | 1.25M | 713.00K | 0.00 |
| InterestIncome | 1.62M | 2.66M | 928.00K | 45.90K |
| NormalizedIncome | -40.77M | -50.58M | -53.29M | -44.16M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -40.67M | -50.73M | -53.01M | -44.16M |
| TotalExpenses | 50.88M | 57.48M | 54.75M | 58.65M |
| RentExpenseSupplemental | 716.00K | 899.00K | ||
| TotalOperatingIncomeAsReported | -41.50M | -52.15M | -53.23M | -43.71M |
| DilutedAverageShares | 56.33M | 45.75M | 35.65M | 31.29M |
| BasicAverageShares | 56.33M | 45.75M | 35.65M | 31.29M |
| DilutedEPS | -0.72 | -1.11 | -1.49 | -1.41 |
| BasicEPS | -0.72 | -1.11 | -1.49 | -1.41 |
| DilutedNIAvailtoComStockholders | -40.67M | -50.73M | -53.01M | -44.16M |
| NetIncomeCommonStockholders | -40.67M | -50.73M | -53.01M | -44.16M |
| NetIncome | -40.67M | -50.73M | -53.01M | -44.16M |
| NetIncomeIncludingNoncontrollingInterests | -40.67M | -50.73M | -53.01M | -44.16M |
| NetIncomeContinuousOperations | -40.67M | -50.73M | -53.01M | -44.16M |
| TaxProvision | 0.00 | 495.00K | ||
| PretaxIncome | -40.67M | -50.73M | -53.01M | -43.67M |
| OtherIncomeExpense | 93.00K | -157.00K | 277.00K | |
| SpecialIncomeCharges | 93.00K | -157.00K | 277.00K | 0.00 |
| GainOnSaleOfPPE | 93.00K | -157.00K | 277.00K | |
| ImpairmentOfCapitalAssets | -276.63K | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | 826.00K | 1.42M | 215.00K | 45.90K |
| InterestExpenseNonOperating | 796.00K | 1.25M | 713.00K | 0.00 |
| InterestIncomeNonOperating | 1.62M | 2.66M | 928.00K | 45.90K |
| OperatingIncome | -41.59M | -51.99M | -53.50M | -43.71M |
| OperatingExpense | 50.88M | 57.48M | 54.75M | 58.65M |
| ResearchAndDevelopment | 36.30M | 40.80M | 38.58M | 41.35M |
| SellingGeneralAndAdministration | 14.59M | 16.68M | 16.17M | 17.31M |
| GeneralAndAdministrativeExpense | 14.59M | 16.68M | 16.17M | 17.31M |
| OtherGandA | 14.59M | 16.68M | 5.89M | 17.31M |
| RentAndLandingFees | 716.00K | 899.00K | ||
| SalariesAndWages | 8.93M | 9.38M | ||
| TotalRevenue | 9.29M | 5.49M | 1.25M | 14.94M |
| OperatingRevenue | 9.29M | 5.49M | 1.25M | 14.94M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 61.82M | 47.22M | 43.04M | 32.20M |
| ShareIssued | 61.82M | 47.22M | 43.04M | 32.20M |
| TotalDebt | 8.88M | 14.70M | 19.32M | 10.05M |
| TangibleBookValue | 17.50M | 37.09M | 65.68M | 65.49M |
| InvestedCapital | 21.83M | 45.25M | 75.68M | 65.49M |
| WorkingCapital | 11.45M | 34.37M | 65.64M | 55.68M |
| NetTangibleAssets | 17.50M | 37.09M | 65.68M | 65.49M |
| CapitalLeaseObligations | 4.54M | 6.53M | 9.32M | 10.05M |
| CommonStockEquity | 17.50M | 37.09M | 65.68M | 65.49M |
| TotalCapitalization | 17.50M | 41.29M | 73.72M | 65.49M |
| TotalEquityGrossMinorityInterest | 17.50M | 37.09M | 65.68M | 65.49M |
| StockholdersEquity | 17.50M | 37.09M | 65.68M | 65.49M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -96.00K | 0.00 | |
| OtherEquityAdjustments | -96.00K | |||
| RetainedEarnings | -341.86M | -301.19M | -250.46M | -197.45M |
| AdditionalPaidInCapital | 359.30M | 338.23M | 316.19M | 262.91M |
| CapitalStock | 62.00K | 47.00K | 43.00K | 32.20K |
| CommonStock | 62.00K | 47.00K | 43.00K | 32.20K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 14.69M | 24.45M | 25.60M | 17.91M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.00M | 7.36M | 14.05M | 5.12M |
| NonCurrentDeferredLiabilities | 0.00 | |||
| NonCurrentDeferredRevenue | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 1.00M | 7.36M | 14.05M | 5.12M |
| LongTermCapitalLeaseObligation | 1.00M | 3.16M | 6.02M | 5.12M |
| LongTermDebt | 4.20M | 8.04M | ||
| CurrentLiabilities | 13.69M | 17.08M | 11.55M | 12.79M |
| OtherCurrentLiabilities | 1.00 | |||
| CurrentDeferredLiabilities | 85.00K | 2.11M | 0.00 | 645.34K |
| CurrentDeferredRevenue | 85.00K | 2.11M | 0.00 | 645.34K |
| CurrentDebtAndCapitalLeaseObligation | 7.87M | 7.33M | 5.26M | 4.93M |
| CurrentCapitalLeaseObligation | 3.54M | 3.37M | 3.30M | 4.93M |
| CurrentDebt | 4.33M | 3.96M | 1.96M | |
| OtherCurrentBorrowings | 4.33M | 3.96M | 1.96M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.81M | 2.22M | 2.27M | 2.01M |
| PayablesAndAccruedExpenses | 3.92M | 5.42M | 4.01M | 5.20M |
| CurrentAccruedExpenses | 1.10M | 1.92M | 1.28M | 2.61M |
| Payables | 2.82M | 3.50M | 2.73M | 2.59M |
| AccountsPayable | 2.82M | 3.50M | 2.73M | 2.59M |
| TotalAssets | 32.19M | 61.53M | 91.28M | 83.40M |
| TotalNonCurrentAssets | 7.05M | 10.08M | 14.10M | 14.93M |
| OtherNonCurrentAssets | 257.00K | 268.00K | 278.00K | 290.00K |
| NonCurrentPrepaidAssets | 1.96M | 2.69M | 3.12M | 2.72M |
| NetPPE | 4.84M | 7.12M | 10.70M | 11.92M |
| AccumulatedDepreciation | -3.68M | -3.62M | -4.24M | -3.44M |
| GrossPPE | 8.52M | 10.73M | 14.94M | 15.37M |
| Leases | 118.00K | 118.00K | 118.00K | 6.53K |
| ConstructionInProgress | 0.00 | |||
| OtherProperties | 8.15M | 10.39M | 5.25M | 15.01M |
| MachineryFurnitureEquipment | 248.00K | 224.00K | 377.00K | 346.13K |
| BuildingsAndImprovements | 6.32M | 9.20M | 9.81M | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 25.14M | 51.45M | 77.19M | 68.47M |
| OtherCurrentAssets | 805.00K | 955.00K | 841.00K | 954.79K |
| PrepaidAssets | 929.00K | 287.00K | 954.79K | |
| Receivables | 945.00K | 1.70M | 57.00K | 3.14M |
| AccountsReceivable | 945.00K | 1.70M | 57.00K | 3.14M |
| CashCashEquivalentsAndShortTermInvestments | 22.46M | 48.51M | 76.29M | 64.37M |
| OtherShortTermInvestments | 0.00 | 24.68M | 0.00 | |
| CashAndCashEquivalents | 22.46M | 48.51M | 51.61M | 64.37M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -36.40M | -39.96M | -41.98M | -39.75M |
| RepaymentOfDebt | -4.00M | -2.00M | 0.00 | |
| IssuanceOfDebt | 0.00 | 10.00M | 0.00 | |
| IssuanceOfCapitalStock | 14.22M | 13.39M | 39.30M | 17.38M |
| CapitalExpenditure | -66.00K | -171.00K | -913.04K | |
| InterestPaidSupplementalData | 669.00K | 1.00M | 570.00K | 0.00 |
| EndCashPosition | 22.61M | 48.66M | 51.76M | 64.52M |
| BeginningCashPosition | 48.66M | 51.76M | 64.52M | 75.02M |
| ChangesInCash | -26.05M | -3.10M | -12.76M | -10.50M |
| FinancingCashFlow | 10.24M | 11.86M | 53.66M | 19.23M |
| CashFlowFromContinuingFinancingActivities | 10.24M | 11.86M | 53.66M | 19.23M |
| NetOtherFinancingCharges | -341.00K | -750.13K | ||
| ProceedsFromStockOptionExercised | 18.00K | 473.00K | 4.70M | 2.60M |
| NetCommonStockIssuance | 14.22M | 13.39M | 39.30M | 17.38M |
| CommonStockIssuance | 14.22M | 13.39M | 39.30M | 17.38M |
| NetIssuancePaymentsOfDebt | -4.00M | -2.00M | 10.00M | 0.00 |
| NetLongTermDebtIssuance | -4.00M | -2.00M | 10.00M | 0.00 |
| LongTermDebtPayments | -4.00M | -2.00M | 0.00 | |
| LongTermDebtIssuance | 0.00 | 10.00M | 0.00 | |
| InvestingCashFlow | 32.00K | 25.00M | -24.61M | 9.11M |
| CashFlowFromContinuingInvestingActivities | 32.00K | 25.00M | -24.61M | 9.11M |
| NetInvestmentPurchaseAndSale | 0.00 | 25.00M | -24.45M | 10.00M |
| SaleOfInvestment | 0.00 | 25.00M | 5.00M | 10.00M |
| PurchaseOfInvestment | 0.00 | -29.45M | 0.00 | |
| NetPPEPurchaseAndSale | 32.00K | 2.00K | -165.00K | -891.49K |
| SaleOfPPE | 98.00K | 2.00K | 6.00K | 21.55K |
| PurchaseOfPPE | -66.00K | 0.00 | -171.00K | -913.04K |
| OperatingCashFlow | -36.33M | -39.96M | -41.81M | -38.84M |
| CashFlowFromContinuingOperatingActivities | -36.33M | -39.96M | -41.81M | -38.84M |
| ChangeInWorkingCapital | -4.92M | -934.00K | 356.00K | -4.39M |
| ChangeInOtherWorkingCapital | -2.03M | 2.11M | -645.00K | -7.97M |
| ChangeInOtherCurrentLiabilities | -1.99M | -2.79M | -735.00K | 2.91M |
| ChangeInOtherCurrentAssets | 0.00 | 250.00K | ||
| ChangeInPayablesAndAccruedExpense | -1.91M | 1.36M | -988.00K | 2.35M |
| ChangeInAccruedExpense | -1.23M | 588.00K | -1.07M | 1.83M |
| ChangeInPayable | -678.00K | 770.00K | 83.00K | 520.40K |
| ChangeInAccountPayable | -678.00K | 770.00K | 83.00K | 520.40K |
| ChangeInPrepaidAssets | 243.00K | 25.00K | -361.00K | -198.95K |
| ChangeInReceivables | 753.00K | -1.64M | 3.08M | -1.73M |
| ChangesInAccountReceivables | 753.00K | -1.64M | 3.08M | -1.73M |
| OtherNonCashItems | 167.00K | 167.00K | -137.00K | |
| StockBasedCompensation | 6.85M | 8.18M | 9.50M | 11.52M |
| AmortizationOfSecurities | 0.00 | -234.00K | -321.00K | -4.58K |
| DepreciationAmortizationDepletion | 2.35M | 3.44M | 1.81M | -1.78M |
| DepreciationAndAmortization | 2.35M | 3.44M | 1.81M | -1.78M |
| Depreciation | 2.35M | 3.44M | 1.81M | -1.78M |
| OperatingGainsLosses | -93.00K | 157.00K | 4.00K | -21.55K |
| GainLossOnSaleOfPPE | -93.00K | 157.00K | 4.00K | -21.55K |
| NetIncomeFromContinuingOperations | -40.67M | -50.73M | -53.01M | -44.16M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CUE
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|